Paulsenkidd1893

Lung cancer is a heterogeneous disease, and the availability of comprehensive genomic profiling has allowed for the characterization of its molecular subtypes. This has increased the ability to deliver "personalized medicines" by tailoring therapies to target driver mutations in a patient's cancer. The development of targeted therapies for non-small cell lung cancer (NSCLC) has helped define the era of precision medicine throughout oncology. This article aims to contextualize recent research and provide an updated summary of targeted therapies available for patients with NSCLC. With practitioners and clinical researchers in mind, we note standard of care therapies, important approvals, practice guidelines, and treatments in development. The first section discusses mutations in the epidermal growth factor receptor (EGFR) gene, and the second section examines rearrangements in the anaplastic lymphoma kinase (ALK) and ROS1 fusions. Finally, we explore the rarer molecular alterations in BRAF, RET, MET, HER2, and KRAS. Given the many available therapies, it is important to understand the molecular alterations in NSCLC, and how to target them.Congenital prosopagnosia (CP) is a life-long impairment in face recognition that occurs in the absence of any known brain damage. It is still unclear whether this disorder is related to a visual deficit, or to an impairment in encoding, maintaining or retrieving a face from memory. We tested CPs and matched neurotypical controls using a delayed estimation task in which a target face was shown either upright or inverted. Participants were asked to select the target face out of a cyclic space of morphed faces that could either resemble the target face, or not. The inclusion of upright and inverted faces enabled to examine the extent of the face inversion effect, a well-known face specific effect often associated with holistic processing. To enable disentangling visual from mnemonic processing, reports were required either following 1 and 6 sec retention interval, or simultaneously while the target face was still visible. Controls showed slower forgetting of upright compared to inverted faces. In contrast, CPs exhibited rapid forgetting of upright faces that was comparable to their performance and to performance of controls on inverted faces. Such forgetting was evident in random errors in which the selected faces did not resemble the face in memory, implying a time related decrease in the probability to access the correct face in memory. Importantly, CPs exhibited no inversion effect across all retention intervals, including the simultaneous one, suggesting that their abnormal rapid forgetting could be explained by an impairment in holistic visual processing of upright faces.Objective A systematic review of research assessing factors associated with inpatient psychiatric readmission of children and adolescents. click here Methods In accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), we searched 8 databases (1994-2018) to identify relevant articles on factors associated with youth psychiatric readmission. Selected articles addressed one or more factors associated with psychiatric readmission for children and adolescents (≤21 years of age) admitted to a psychiatric hospital in the United States for a primary mental health diagnosis. Two authors independently reviewed article abstracts, titles, and text. Results Of 7903 retrieved articles, 30 studies met inclusion criteria. Analyzed variables were categorized according to child demographic and clinical characteristics; family, provider, and community characteristics; and treatment and aftercare characteristics. Available studies were markedly heterogeneous in methodology and outcomes. Factors associated with an increased risk of readmission included greater symptom severity, clinical diagnoses such as psychosis and affective disorders, suicidal behavior and self-injury, poor family functioning, and longer lengths of index hospital stay. Conclusions Controlled trials of interventions to improve care and reduce recidivism for psychiatrically hospitalized youth are needed. Future research will benefit from a guiding theoretical framework, more representative samples, and standardized exposure/outcome measures.Objective Cleft lip and palate is the main craniofacial malformation in France. Many surgical techniques had been described to restore cleft palate. In this study, we evaluate phonation in a homogeneous series of patient with isolated unilateral non-syndromic cleft lip and palate before (and after) alveolar cleft closure, operated according to our surgical protocol. Methods We included retrospectively 71 patients with isolated non-syndromic unilateral cleft lip and palate (UCLP), operated in our department from 2009 to 2013. All patients underwent the same surgical protocol modified Millard cheilorhinoplasty (from 5 to 9 month-old); direct hard palatal closure (from 12 to 20 month-old); alveolar cleft closure with cancellous iliac bone graft (from 4 to 6 year-old). The phonation and clinical statute were evaluated before and after alveolar cleft closure. Fistula rate and speech evaluation were recorded. Results The rate of oronasal fistula was 12.7%. About phonation, 76% and 86% of patients were competent or borderline competent respectively before and after gingivoperiostoplasty. Conclusion This surgical protocol provided speech results in patients with isolated unilateral non-syndromic cleft lip and palate. The gingivoperiostoplasty improved the speech intelligibility.Over the past 10 years, there has been substantial progress in the study and implementation of lung cancer screening using low-dose computed tomography (LDCT). The National Lung Screening Trial, the recently reported NELSON (NEderlands-Leuvens Longkanker Screenings ONderzoek) trial, and other European trials provide strong evidence for the efficacy of LDCT to reduce lung cancer mortality. This has resulted in the United State's Preventative Task Force and numerous professional medical societies adopting lung cancer screening recommendations. Despite the general acceptance of the positive effect of screening, low adoption and implementation rates remain nationally. In this article, the authors discuss the evolution and current state of the evidence for LDCT screening for lung cancer. The authors will also review the associated risks, cost, and challenges of implementation of an LDCT screening program.